|
CN104202977A
|
|
Tris(hydroxymethyl)aminomethane salts of a small-molecule GLP1R agonist and pharmaceutical compositions and uses thereof
|
|
WO2012096824A1
|
|
Phenylglyoxylic acid derivatives and their preparation and use
|
|
AU2011265421A1
|
|
Urea glucokinase activators
|
|
AU2011226965A1
|
|
Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
|
|
CN102906077A
|
|
Use of metformin in combination with glucokinase activator and compositions comprising metformin and glucokinase activator
|
|
CA2788355A1
|
|
Phenyl-heteroaryl derivatives and methods of use thereof
|
|
CA2772797A1
|
|
Substituted imidazole derivatives
|
|
WO2011031620A1
|
|
Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the same
|
|
TN2010000373A1
|
|
The present invention provides oxadiazoanthracene
|
|
WO2011102845A1
|
|
Rage fusion protein compositions and methods of use
|
|
BRPI1013579A2
|
|
substituted azoanthracene derivatives, pharmaceutical compositions and methods of using them
|
|
WO2009126709A1
|
|
Ligands for the glp-1 receptor and methods for discovery thereof
|
|
EA018225B1
|
|
Oxadiazoanthracene compounds for the treatment of diabetes
|
|
CN101677562A
|
|
Novel compounds
|
|
CN101663280A
|
|
crystalline forms i and ii of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl}-phenoxy)-propyl]-diethyl-amine
|
|
EP2144883A1
|
|
Crystalline forms i and ii of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl}-phenoxy)-propyl]-diethyl-amine
|
|
CA2667287A1
|
|
Mandelic acid derivatives and preparation thereof
|
|
AU2007203289A1
|
|
Carboxamide derivatives as therapeutic agents
|
|
EP2038256A1
|
|
6- (4-cyclopropylpiperazin-1-yl) -2 ' -methyl- [3, 4 ']-bipyridine and its use as a medicament
|
|
CA2669708A1
|
|
Benzamide glucokinase activators
|
